Answer: TB
Notes: India will train healthcare professionals to use the BPalM regimen for treating multidrug-resistant tuberculosis (MDR-TB). The BPalM regimen includes bedaquiline, pretomanid, linezolid, and moxifloxacin. Recommended by WHO in 2022, it's already available in nearly 40 countries. The BPalM regimen is more effective, has fewer side effects, and shortens treatment time from 18-24 months to six months. It also helps prevent TB transmission, making it crucial for India's goal to eliminate TB by 2025, as the country has 27% of global TB cases.
